|
|
Impact of Endostar Combined With Chemotherapy on the Angiogenesis of Advanced Non-Small Cell Lung Cancer (NSCLC)
Basic Trial Information Trial Description Summary Further Trial Information Eligibility Criteria Trial Contact Information
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Biomarker/Laboratory analysis, Treatment
|
|
|
|
Active
|
|
|
|
18 to 75
|
|
|
|
Other
|
|
|
|
XJ-EnXS0802 NCT00657423
|
|
|
Trial Description
Summary To study the impact of endostar combined with docetaxel and cisplatin on the angiogenesis of non-small cell lung cancer, patients will be randomly assigned to the group one (endostar combined with docetaxel and cisplatin) and group two (docetaxel and cisplatin). - The serum concentrations of Endostatin,VEGF and bFGF are determined.
- Blood circulating endothelial cells (CECs) and circulating hematopoietic progenitor cells (CPCs) will be measured by flow cytometer.
- Statistical analysis will be applied to study the relationship between the levels of Endostatin, VEGF, bFGF, CECs and CPCs and the clinical outcomes such as objective response rate(ORT), time to progression (TTP), mean survival time(MST), toxicity and quality of life (QOL).
Further Study Information To study the impact of endostar combined with docetaxel and cisplatin on the angiogenesis of non-small cell lung cancer,patients will be randomly assigned to the experimental group(endostar combined with docetaxel and cisplatin) and the control group (docetaxel and cisplatin). - the serum concentrations of Endostatin,VEGF and bFGF are determined.
- Blood circulating endothelial cells (CECs) and circulating hematopoietic progenitor cells (CPCs) will be measured by flow cytometer.
- the clinical parameters such as objective response rate (ORT),time to progression(TTP) and mean survival time(MST) will be collected according to the WHO criteria.
- the toxicity will be recorded according to the NCI-CTC v3.0.
- the Quality of life was self-assessed using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ C-30 questionnaire.
- Statistical analysis will be applied to study the relationship between the levels of Endostatin,VEGF,bFGF,CECs and CPCs and the clinical outcomes such as ORT, TTP, MST, toxicity and QOL.
Eligibility Criteria Inclusion Criteria: - Clinical diagnosis of advanced or metastatic NSCLC (confirmed histologically, with a tumor that was measurable by clinical and/or radiologic examination.
- Have an Eastern Cooperative Oncology Group performance status 0 to 2.
- Adequate renal, cardiac, hepatic, and hematologic function as indicated by the following parameters: absolute neutrophil count 2 x the ninth power of ten/L, thrombocytes 100 x the ninth power of ten/L, hemoglobin 10 g/dL, total bilirubin 1.25x the upper limit of normal range (ULN), ALT and AST 1.5x ULN, alkaline phosphatase 5x ULN, creatinine 1.15x ULN.
Exclusion Criteria: - Known brain metastases or secondary neoplasia.
- Myocardial insufficiency or myocardial infarction within the preceding 6 months.
- Severe renal or hepatic insufficiency.
- Pre-existing motor or sensor neurotoxicity WHO grade 2.
- Severe psychologic disease.
- Active infection, or other condition that could compromise protocol compliance.
- Simultaneous administration of other antineoplastic medications.
- Clinically significant hemoptysis.
- Pregnancy and/or lactation.
Trial Contact Information
Trial Lead Organizations/Sponsors Xijing Hospital of the Fourth Military Medical University Yantai Medgenn Company, Limited
Changgui Wu, MD, PHD | | Principal Investigator |
Trial Sites
|
|
|
|
China |
|
|
Xi'an |
|
| | | | | | | Xijing Hospital of the Fourth Military Medical University |
| | Shengqing Li, MD. PHD. |
Ph: 086-029-84771132 |
|
Email:
shengqingli@gmail.com |
|
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00657423 Information obtained from ClinicalTrials.gov on August 05, 2008 Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov. Back to Top |
|